Related references
Note: Only part of the references are listed.Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience
Christopher J. DiBlasio et al.
BJU INTERNATIONAL (2009)
Time to Prostate-Specific Antigen Nadir Independently Predicts Overall Survival in Patients Who Have Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen-Deprivation Therapy
Toni K. Choueiri et al.
CANCER (2009)
Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art
Andrew V. Schally
BJU INTERNATIONAL (2007)
Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up
Hideyuki Akaza et al.
BJU INTERNATIONAL (2006)
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162)
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Androgen-deprivation therapy as primary treatment for localized prostate cancer - Data from cancer of the prostate strategic urologic research endeavor (CaPSURE)
J Kawakami et al.
CANCER (2006)
Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer
DM Janoff et al.
BJU INTERNATIONAL (2005)
Androgen deprivation therapy for prostate cancer
N Sharifi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma
VB Shahinian et al.
CANCER (2005)
Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer
J Morote et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE)
MR Cooperberg et al.
JOURNAL OF UROLOGY (2003)
National practice patterns and time trends in androgen ablation for localized prostate cancer
MR Cooperberg et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Recent trends in prostate cancer incidence and mortality in Southeast England
HS Evans et al.
EUROPEAN UROLOGY (2003)
Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer
C Kwak et al.
JOURNAL OF UROLOGY (2002)
Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era
MG Oefelein et al.
UROLOGY (2002)
Nadir prostate-specific antigen as a predictor of progression to an drogen-independent prostate cancer
EA Benaim et al.
UROLOGY (2002)
Share Paper
